Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : HLD-0915
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Deep Track Capital
Deal Size : $126.0 million
Deal Type : Series B Financing
Halda Therapeutics Secures $126 Million Financing to Advance RIPTAC™ Cancer Therapies
Details : The proceeds from the financing will be used to advance two RIPTAC candidates into clinical trials, including HLD-0915, for patients with prostate cancer and breast cancer.
Brand Name : HLD-0915
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 12, 2024
Lead Product(s) : HLD-0915
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Deep Track Capital
Deal Size : $126.0 million
Deal Type : Series B Financing
Lead Product(s) : Regulated Induced Proximity Targeting Chimeras Therapeutic
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : RIPTAC is a bifunctional small molecules that selectively target tumors by holding a tumor-specific protein and a protein with essential function together in a trimeric complex which involves the formation of neo protein-protein-interactions.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 14, 2023
Lead Product(s) : Regulated Induced Proximity Targeting Chimeras Therapeutic
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?